KemPharm, Inc. announced that Richard W. Pascoe, who has been serving as Executive Chairman, will transition into the role of Chief Executive Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.82 USD | +0.42% | -6.59% | -26.41% |
May. 13 | Transcript : Zevra Therapeutics, Inc. - Shareholder/Analyst Call | |
May. 08 | Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.41% | 202M | |
+15.09% | 78.37B | |
+11.65% | 9.08B | |
+54.35% | 4.85B | |
-12.85% | 5.06B | |
+1.60% | 3.85B | |
-20.85% | 2.36B | |
+16.88% | 2.37B | |
-29.25% | 2.22B | |
+24.62% | 2.27B |
- Stock Market
- Equities
- ZVRA Stock
- News Zevra Therapeutics, Inc.
- KemPharm, Inc. Appoints Richard W. Pascoe, as Chief Executive Officer